NCT00126542View on ClinicalTrials.gov

Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

January 31, 2007

Study Completion Date

April 30, 2010

Conditions
Fallopian Tube CancerPrimary Peritoneal Cavity CancerRecurrent Ovarian Epithelial CancerStage IV Ovarian Epithelial Cancer
Interventions
BIOLOGICAL

bevacizumab

Given IV

DRUG

erlotinib hydrochloride

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

60637

University of Chicago, Chicago

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00126542 - Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | Biotech Hunter | Biotech Hunter